The latest from BioStock
» Ultimovacs about its cancer vaccine
» Aptahem enters into agreement with CRO for phase I studies
» Strong additions and clinical focus in Scandion Oncology's Q1
» Targinta takes the lead in the ADC field in the Nordics
» New findings support use of RhoVac's cancer vaccine in multiple cancers
Read BioStock's newsletter for v.20 here.
Don't miss June 8-9!
Morning news
Sanionas Clinical study on hypothalamic obesity published in scientific journal. Read more.
Iconovos event partner Marking signs an agreement with Gerresheimer for large-scale production of ICOone Nasal. Read more.
Initiator Pharma announces positive efficacy data in the phase I study regarding the effect of IP2015 on pain reduction. Read more.
Invent Medics Efemia menstrual cup is launched in the Swedish mountains and contributes to sustainable mountain tourism. Read more.
The outcome of redemption in Amniotic warrants of series TO1 have been published. Read more.
Diagonal Bio receives Intention to Grant from European Patent Office regarding a patent application. Read more.
Hansa Biopharma has completed recruitment for a phase II study of imlifidase during kidney transplantation. Read more.
Increased market access when Immunovia obtains licensing rights for clinical laboratories in additional US states. Read more.
The pharmaceutical industry launches a sustainability manifesto. Read more.
Changes in Orphazymes board. Read more.
Qlucore is expanding with another area of cancer diagnostics. Read more.
AstraZeneca aims to transform cancer care with enhertudata at ASCO 2022. Read more. Vaxzevria approved as a third booster dose in the EU. Read more.
Self-testing for HPV provides major health benefits for women in Skåne. Read more.
Bedrocan and Aurora will participate in Stockholm Medical Cannabis 2022. Read more.
Bavarian Nordic has updated the articles of association. Read more.
Upcoming presentations:
2cureX CellaVision
Interim reports:
Cantargia Inhalation Sciences Prolight Diagnostics
Notices to the Annual General Meeting:
PharmaLundensis
Communiqués:
Abliva BioWorks Medfield Diagnostics PExA Prolight Diagnostics SynAct Pharma
Notifications of share transactions and changes in equity:
Bavarian Nordic CS Medica Revenio Group QuiaPEG
News received since Friday lunch
Xintela has decided on a new share issue of SEK 44,6 million and a supplementary directed share issue of SEK 10 million. Read moreThe company has also released its Q1 report. Read more.
May 25th is the last day for trading BTA in PolarCool. Read more.
Spermosis has entered into an agreement regarding clinical validation to obtain CE marking. Read moreThe company has also clarified the potential. Read more.
Donation from Lundberg Research Foundation enables a study on kidney transplantation with the potential to shorten waiting lists. Read more.
Positive preclinical effects of Cantargias CAN10 in case of atherosclerosis. Read more.
CS Medica follows up on participation in Innovation Tours 2022 of Vitafoods Europe 2022. Read more.
This morning's price development
Winner: Brighter 41,3%, I-tech 11,7%, Lipigon 11,4%, Micropos Medical 10,8%, RLS Global 9,6%
Förlorare: Xintela -57,1%, Odinwell -15,7%, WntResearch -11,7%, Calmark -8,6%, Bonzun -8,1%
Index: OMXS30 2008 0,70%, Healthcare 0,15%
More articles from BioStock
» Seattle Sperm Bank on the Letter of Intent with Spermosens
» Cyxone focuses on the RA program
» Carbiotix CEO on the capital round and the US launch
» BioStock Studio: Cereno Scientific summarizes the first quarter of the year
» Immunicum delivers positive phase II data in AML